United States Biotechnology & Medical Research

VivoSim Labs Inc (VIVS)

VivoSim Labs Inc experienced one notable purchase recently. Chief Commercial Officer Lialin Tony Serge acquired 10,000 shares valued at $2,804 on August 31, 2026. This activity follows a significant 59.5% decline in stock price over the past quarter, occurring shortly after the latest results financiers were released.
Ticker: VIVS Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for VivoSim Labs Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Lialin Tony Serge Chief Commercial Officer Officer
Transaction date
Purchase
Price
160.39
Quantity 60,828 -34.8%
Value US$569,548
3.3
Gobel David Non-Executive Director
Transaction date
Sale
Price
207.97
Quantity 4,750 -16.7%
Value US$3,459,936
3.3
Gobel David Director Non-Executive Director
Transaction date
Proposed sale
Price
392.25
Quantity 15,365
Value US$3,933,000
Hughes Steven George Chief Medical Officer Officer
Transaction date
Sale
Price
0.29
Quantity 22,230 -13.8%
Value US$6,431
Presnell Sharon Collins Chief Scientific Officer Officer
Transaction date
Planned sale
Price
1.27
Quantity 40,000 -12.0%
Value US$50,800
Murphy Keith Former affiliate last filing
Transaction date
Purchase
Price
1.49
Quantity 200,500 +3.2%
Value US$299,346
Murphy Keith Former affiliate last filing
Transaction date
Purchase
Price
1.50
Quantity 135,000 +2.2%
Value US$201,960
3.0
Murphy Keith Chairman, CEO and President Executive Director
Transaction date
Planned sale
Price
3.68
Quantity 25,000 -0.4%
Value US$92,035
3.0
Murphy Keith Chairman, CEO and President Executive Director
Transaction date
Planned sale
Price
3.50
Quantity 20,100 -0.3%
Value US$70,440
3.0
Murphy Keith Chairman, CEO and President Executive Director
Transaction date
Planned sale
Price
3.51
Quantity 4,900 -0.1%
Value US$17,215
Murphy Keith Chairman, CEO and President Executive Director
Transaction date
Planned sale
Price
3.72
Quantity 50,000 -0.8%
Value US$185,955
David Eric CSO & EVP Pre-Clinical Dev Officer
Transaction date
Planned sale
Price
4.55
Quantity 20,000 -2.8%
Value US$91,000
GLOVER JAMES T Non-Executive Director
Transaction date
Purchase
Price
2.80
Quantity 10,000 New position
Value US$28,000
3.0
Murphy Keith Chairman, CEO and President Executive Director
Transaction date
Purchase
Price
2.56
Quantity 20,000 +0.3%
Value US$51,188
MICHAELS BARRY D Chief Financial Officer Officer
Transaction date
Planned sale
Price
7.50
Quantity 10,500 -3.5%
Value US$78,771
David Eric Chief Strategy Officer Officer
Transaction date
Planned sale
Price
7.56
Quantity 16,300 -2.3%
Value US$123,243
MICHAELS BARRY D Chief Financial Officer Officer
Transaction date
Planned sale
Price
7.50
Quantity 4,500 -1.5%
Value US$33,750
Renard Michael EVP of Commercial Operations Officer
Transaction date
Planned sale
Price
10.65
Quantity 10,000 -100.0%
Value US$106,500
Renard Michael EVP of Commercial Operations Officer
Transaction date
Planned sale
Price
9.93
Quantity 30,000 -100.0%
Value US$297,999
Renard Michael EVP of Commercial Operations Officer
Transaction date
Planned sale
Price
8.92
Quantity 10,000 -100.0%
Value US$89,200
David Eric Chief Strategy Officer Officer
Transaction date
Sale
Price
10.39
Quantity 16,470 -2.2%
Value US$171,105
Murphy Keith Chairman, CEO and President Executive Director
Transaction date
Planned sale
Price
6.63
Quantity 30,000 -0.5%
Value US$198,990
0.5
David Eric Chief Strategy Officer Officer
Transaction date
Sale
Price
5.66
Quantity 3,530 -0.5%
Value US$19,996
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-09-01 2026-08-31 B Purchase
Lialin Tony Serge

Chief Commercial Officer

Officer
60,828 -34.8%
160.39
US$569,548 		60,828 -34.8% 160.39 US$569,548
2023-11-17 2023-11-15 S Sale
3.3
Gobel David
Non-Executive Director
4,750 -16.7%
207.97
US$3,459,936 		4,750 -16.7% 207.97 US$3,459,936
2023-11-15 2023-11-15 PrS Proposed sale
3.3
Gobel David

Director

Non-Executive Director
15,365
392.25
US$3,933,000 		15,365 392.25 US$3,933,000
2019-08-19 2019-08-16 S Sale Hughes Steven George

Chief Medical Officer

Officer
22,230 -13.8%
0.29
US$6,431 		22,230 -13.8% 0.29 US$6,431
2018-11-13 2018-11-08 PlS Planned sale Presnell Sharon Collins

Chief Scientific Officer

Officer
40,000 -12.0%
1.27
US$50,800 		40,000 -12.0% 1.27 US$50,800
2017-12-04 2017-11-24 B Purchase Murphy Keith

Former affiliate last filing
200,500 +3.2%
1.49
US$299,346 		200,500 +3.2% 1.49 US$299,346
2017-12-04 2017-11-22 B Purchase Murphy Keith

Former affiliate last filing
135,000 +2.2%
1.50
US$201,960 		135,000 +2.2% 1.50 US$201,960
2017-02-10 2017-02-09 PlS Planned sale
3.0
Murphy Keith

Chairman, CEO and President

Executive Director
25,000 -0.4%
3.68
US$92,035 		25,000 -0.4% 3.68 US$92,035
2017-01-25 2017-01-24 PlS Planned sale
3.0
Murphy Keith

Chairman, CEO and President

Executive Director
20,100 -0.3%
3.50
US$70,440 		20,100 -0.3% 3.50 US$70,440
2017-01-25 2017-01-23 PlS Planned sale
3.0
Murphy Keith

Chairman, CEO and President

Executive Director
4,900 -0.1%
3.51
US$17,215 		4,900 -0.1% 3.51 US$17,215
2016-12-15 2016-12-14 PlS Planned sale Murphy Keith

Chairman, CEO and President

Executive Director
50,000 -0.8%
3.72
US$185,955 		50,000 -0.8% 3.72 US$185,955
2016-08-09 2016-08-05 PlS Planned sale David Eric

CSO & EVP Pre-Clinical Dev

Officer
20,000 -2.8%
4.55
US$91,000 		20,000 -2.8% 4.55 US$91,000
2015-08-13 2015-08-13 B Purchase GLOVER JAMES T Non-Executive Director
10,000 New position
2.80
US$28,000 		10,000 New position 2.80 US$28,000
2015-08-13 2015-08-12 B Purchase
3.0
Murphy Keith

Chairman, CEO and President

Executive Director
20,000 +0.3%
2.56
US$51,188 		20,000 +0.3% 2.56 US$51,188
2014-12-31 2014-12-30 PlS Planned sale MICHAELS BARRY D

Chief Financial Officer

Officer
10,500 -3.5%
7.50
US$78,771 		10,500 -3.5% 7.50 US$78,771
2014-12-31 2014-12-30 PlS Planned sale David Eric

Chief Strategy Officer

Officer
16,300 -2.3%
7.56
US$123,243 		16,300 -2.3% 7.56 US$123,243
2014-12-31 2014-12-29 PlS Planned sale
MICHAELS BARRY D

Chief Financial Officer

Officer
4,500 -1.5%
7.50
US$33,750 		4,500 -1.5% 7.50 US$33,750
2014-02-21 2014-02-21 PlS Planned sale
Renard Michael

EVP of Commercial Operations

Officer
10,000 -100.0%
10.65
US$106,500 		10,000 -100.0% 10.65 US$106,500
2014-01-29 2014-01-29 PlS Planned sale Renard Michael

EVP of Commercial Operations

Officer
30,000 -100.0%
9.93
US$297,999 		30,000 -100.0% 9.93 US$297,999
2014-01-29 2014-01-27 PlS Planned sale Renard Michael

EVP of Commercial Operations

Officer
10,000 -100.0%
8.92
US$89,200 		10,000 -100.0% 8.92 US$89,200
2013-11-15 2013-11-13 S Sale David Eric

Chief Strategy Officer

Officer
16,470 -2.2%
10.39
US$171,105 		16,470 -2.2% 10.39 US$171,105
2013-10-18 2013-10-18 PlS Planned sale Murphy Keith

Chairman, CEO and President

Executive Director
30,000 -0.5%
6.63
US$198,990 		30,000 -0.5% 6.63 US$198,990
2013-10-15 2013-10-10 S Sale
0.5
David Eric

Chief Strategy Officer

Officer
3,530 -0.5%
5.66
US$19,996 		3,530 -0.5% 5.66 US$19,996
Explore more

More insider trading research around VivoSim Labs Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America